These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12930449)

  • 21. Granins and prostate cancer.
    Deftos LJ; Abrahamsson PA
    Urology; 1998 May; 51(5A Suppl):141-5. PubMed ID: 9610570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
    Ahel MZ; Kovacic K; Tarle M
    Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
    Di Silverio F; Sciarra A
    J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
    Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
    Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum chromogranin-A in advanced prostate cancer.
    Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
    BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
    Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
    Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating neuroendocrine markers in patients with prostate carcinoma.
    Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
    Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate.
    Deftos LJ; Nakada S; Burton DW; di Sant'Agnese PA; Cockett AT; Abrahamsson PA
    Urology; 1996 Jul; 48(1):58-62. PubMed ID: 8693652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
    Tarle M; Ahel MZ; Kovacić K
    Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
    Cerulli C; Sciarra A; Salvatori G; Di Silverio F
    Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial comment.
    Loeb S
    Urology; 2014 Mar; 83(3):596-7; discussion 597-8. PubMed ID: 24581522
    [No Abstract]   [Full Text] [Related]  

  • 37. Is prostate-specific antigen a reliable marker of bone metastasisin patients with newly diagnosed cancer of the prostate?
    Gontero P; Muir GH
    Eur Urol; 1998 Dec; 34(6):518-9. PubMed ID: 9831795
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial comment.
    Epstein JI
    Urology; 2013 Jul; 82(1):152-3; discussion 153. PubMed ID: 23706589
    [No Abstract]   [Full Text] [Related]  

  • 39. Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA.
    Patel HD; Chalfin HJ; Carter HB
    JAMA Oncol; 2016 Jul; 2(7):867-8. PubMed ID: 27031887
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical evidence of neuroendocrine differentiation in a patient with prostate cancer and bone marrow micrometastases.
    Sciarra A; Bosman C; Schillaci O; Monti M; Di Chiro C; Di Silverio F
    BJU Int; 2001 Jan; 87(1):123-5. PubMed ID: 11122006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.